Journal
ACS CHEMICAL NEUROSCIENCE
Volume 8, Issue 12, Pages 2778-2790Publisher
AMER CHEMICAL SOC
DOI: 10.1021/acschemneuro.7b00314
Keywords
MALDI imaging mass spectrometry; trimodal MALDI imaging MS; Alzheimer's disease; plaque pathology; neuronal lipids; A beta peptides
Funding
- Swedish Research Council VR [2014-6447, 2012-1593, 2012-2288]
- Royal Society of Arts and Sciences in Gothenburg
- Alzheimerfonden
- Demensfonden
- Hjarnfonden
- Jeanssons Stiftelsen
- Ahlen Stiftelsen
- Stiftelsen Gamla Tjanarinnor
- Stohnes Stiftelse
- Torsten Soderberg Foundation
- Stiftelsen Wilhelm och Martina Lundgrens Vetenskapsfond
Ask authors/readers for more resources
Multimodal chemical imaging using matrix assisted laser desorption/ionization mass spectrometry (MALDI-MS) can provide comprehensive molecular information in situ within the same tissue sections. This is of relevance for studying different brain pathologies such as Alzheimer's disease (AD), where recent data suggest a critical relevance of colocalizing A beta peptides and neuronal lipids. We here developed a novel trimodal, high-resolution (10 mu m) MALDI imaging MS (IMS) paradigm for negative and positive ion mode lipid analysis and subsequent protein ion imaging on the same tissue section. Matrix sublimation of 1,5-diaminonaphthalene (1,5-DAN) enabled dual polarity lipid MALDI IMS on the same pixel points at high spatial resolutions (10 mu m) and with high spectral quality. This was followed by 10 mu m resolution protein imaging on the same measurement area, which allowed correlation of lipid signals with protein distribution patterns within distinct cerebellar regions in mouse brain. The demonstrated trimodal imaging strategy (IMS3) was further shown to be an efficient approach for simultaneously probing A beta plaque-associated lipids and A beta peptides within the hippocampus of 18 month-old transgenic AD mice (tgArcSwe). Here, IMS3 revealed a strong colocalization of distinct lipid species including ceramides, phosphatidylinositols, sulfatides (Cer 18:0, PI 38:4, ST 24:0) and lysophosphatidylcholines (LPC 16:0, LPC 18:0) with plaque-associated A beta isoforms (A beta 1-37, A beta 1-38, A beta 1-40). This highlights the potential of IMS3 as an alternative, superior approach to consecutively performed immuno-based A beta staining strategies. Furthermore, the IMS3 workflow allowed for multimodal in situ MS/MS analysis of both lipids and A beta peptides. Altogether, the here presented IMS3 approach shows great potential for comprehensive, high-resolution molecular analysis of histological features at cellular length scales with high chemical specificity. It therefore represents a powerful approach for probing the complex molecular pathology of, e.g., neurodegenerative diseases that are characterized by neurotoxic protein aggregation.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available